Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Oct 7;15(10):1386-1388.
doi: 10.2215/CJN.13430820. Epub 2020 Sep 29.

SGLT2 Inhibitors across the Spectrum of Severity of CKD

Ali Ziaolhagh  1 , Christos Argyropoulos
Affiliations
Editorial

SGLT2 Inhibitors across the Spectrum of Severity of CKD

Ali Ziaolhagh et al. Clin J Am Soc Nephrol. .

Erratum in

  • Correction.
    [No authors listed] [No authors listed] Clin J Am Soc Nephrol. 2020 Dec 31;16(1):127. doi: 10.2215/CJN.16851020. Epub 2020 Nov 25. Clin J Am Soc Nephrol. 2020. PMID: 33239411 Free PMC article. No abstract available.
No abstract available

Keywords: KDIGO risk category; SGLT2 inhibitors; chronic kidney disease; empaglflozin.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Kidney-specific outcomes of SGLT2i in diabetic kidney disease. Hazard ratio (HR) of empagliflozin on MACE-3 (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke; A) and incident/worsening nephropathy (B) by Kidney Disease Improving Global Outcomes (KDIGO) risk category in EMPA-REG OUTCOME; years of postponed kidney failure in the very high risk KDIGO category associated with the use of empagliflozin in EMPA-REG OUTCOME by pretherapy eGFR (C); and meta-analysis of the composite kidney disease outcome of worsening kidney function/ESKD and kidney death across kidney disease outcomes (CREDENCE), cardiovascular safety (CANVAS Program, DECLARE-TIMI-58, EMPA-REG, VERTIS-CV), and heart failure (DAPA-HF) in sodium glucose cotransporter 2 inhibitor (SGLT2i) trials (D). 95% CI, 95% confidence interval; PBO, placebo; PY, person years.
See this image and copyright information in PMC

Comment on

References

    1. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators : Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373: 2117–2128, 2015. - PubMed
    1. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group : Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377: 644–657, 2017. - PubMed
    1. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde A-M, Sabatine MS; DECLARE–TIMI 58 Investigators : Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380: 347–357, 2019. - PubMed
    1. American College of Cardiology: Cardiovascular outcomes following ertugliflozin treatment in patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease, 2020. Available at: https://www.acc.org/education-and-meetings/image-and-slide-gallery/media.... Accessed August 5, 2020
    1. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu P-L, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators : Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380: 2295–2306, 2019. - PubMed

MeSH terms